MedTrace Logo

Sex Differences in Neural Response to Cannabidiol

NCT04777643 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2023-12-21

No results posted yet for this study

Summary

This is a randomized, double-blind, within-subjects, cross-over design to assess neural changes following a single dose of cannabidiol (CBD) (600mg) versus placebo among healthy female volunteers.

Conditions

  • CBD
  • Neural Responses

Interventions

DRUG

Cannabidiol

Participants will receive a single 600mg oral dose of Epidiolex (cannabidiol) 2 hours prior to fMRI scanning.

OTHER

Placebo

Participants will receive a single oral dose of placebo 2 hours prior to fMRI scanning.

Sponsors & Collaborators

  • Yale University

    lead OTHER

Principal Investigators

  • Sarah D. Lichenstein, PhD · Yale University

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-06-07
Primary Completion
2023-04-27
Completion
2023-04-27
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04777643 on ClinicalTrials.gov